Metformin: New Preparations and Nonglycemic Benefits (Q39100209)

9 September 2017

Metformin: New Preparations and Nonglycemic Benefits (English)

1 reference

9 September 2017

1 reference

2

1 reference

9 September 2017

Yoshihito Fujita

1

1 reference

PubMed ID

28116648

9 September 2017

language of work or name

1 reference

1 January 2017

1 reference

9 September 2017

Current diabetes report

1 reference

9 September 2017

17

1 reference

9 September 2017

1

1 reference

9 September 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s11892-017-0829-8

9 September 2017

0 references

cites work

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin: an old but still the best treatment for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Repurposing metformin: an old drug with new tricks in its binding pockets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

The AMP-activated protein kinase pathway--new players upstream and downstream.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Role of AMP-activated protein kinase in mechanism of metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

METFORMIN: NON-GLYCEMIC EFFECTS AND POTENTIAL NOVEL INDICATIONS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

21 January 2018

The "slower" the better.

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin-associated lactic acidosis: Current perspectives on causes and risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin and the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, glucagon and growth hormone in non-diabetic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin and the intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, pla

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Steady-state pharmacokinetics of a novel extended-release metformin formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Effects of body mass index or dosage on gastrointestinal disorders associated with extended-release metformin in type 2 diabetes: Sub-analysis of a Phase IV open-label trial in Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Epidemic obesity and type 2 diabetes in Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

β cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin use and mortality among patients with diabetes and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Improved endothelial function with metformin in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Diabetes and cancer: a consensus report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Significantly increased risk of cancer in diabetes mellitus patients: A meta-analysis of epidemiological evidence in Asians and non-Asians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin and reduced risk of cancer in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin does not alter the risk of lung cancer: a case-control analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Does Metformin Reduce Cancer Risks? Methodologic Considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Repurposing metformin for cancer treatment: current clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Insulin and insulin-like growth factor signalling in neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Immune-mediated antitumor effect by type 2 diabetes drug, metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin induces a dietary restriction-like state and the oxidative stress response to extend C. elegans Healthspan via AMPK, LKB1, and SKN-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin: do we finally have an anti-aging drug?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Aging and survival: the genetics of life span extension by dietary restriction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Action of food restriction in delaying the aging process

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Dietary restriction in C. elegans: from rate-of-living effects to nutrient sensing pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin improves healthspan and lifespan in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin use and mortality in ambulatory patients with diabetes and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin and thiazolidinedione use in Medicare patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Metformin in women with PCOS, cons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Clomiphene, Metformin, or Both for Infertility in the Polycystic Ovary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Consensus on infertility treatment related to polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Clomiphene citrate, metformin or both as first-step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head-to-head randomized controlled studies and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

The role of metformin in the management of NAFLD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Systematic review: Preventive and therapeutic applications of metformin in liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Risk Factors of Vitamin B12 Deficiency in Patients Receiving Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-017-0829-8

Lactic acidosis in patients with diabetes treated with metformin

21 January 2018

1 reference

12 December 2020

Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain

1 reference

12 December 2020

Beneficial effects of metformin on haemostasis and vascular function in man.

1 reference

12 December 2020

Accumulation of metformin by tissues of the normal and diabetic mouse

1 reference

12 December 2020

Metformin and lactic acidosis in an Australian community setting: the Fremantle Diabetes Study

1 reference

12 December 2020

The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies.

1 reference

12 December 2020

Metformin use in women with polycystic ovary syndrome

1 reference

12 December 2020

Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial

1 reference

12 December 2020

Vitamin B12 status in metformin treated patients: systematic review

1 reference

12 December 2020

Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis

1 reference

12 December 2020

Will delayed release metformin provide better management of diabetes type 2?

1 reference

12 December 2020

Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus.

1 reference

12 December 2020

Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications

1 reference

12 December 2020

Should we screen diabetic patients using biguanides for megaloblastic anaemia?

1 reference

12 December 2020

10.1007/S11892-017-0829-8

Identifiers

DOI

1 reference

9 September 2017

1 reference

PubMed ID

28116648